Publications by authors named "Jay Bertrand"

Claim this Profile
M
Mechanism of glycogen synthase inactivation and interaction with glycogenin.
Laura Marr, Dipsikha Biswas, Leonard A Daly, Christopher Browning, Sarah C M Vial, Jay A Bertrand

Nat Commun· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Maria Gabriella Brasca, Paola Gnocchi, Marcella Nesi, Nadia Amboldi, Nilla Avanzi, Jay Bertrand

Bioorg Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Maria Gabriella Brasca, Marcella Nesi, Nilla Avanzi, Dario Ballinari, Tiziano Bandiera, Jay Bertrand

Bioorg Med Chem· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA.
Michael K Swan, Valerie Legris, Adam Tanner, Philip M Reaper, Sarah Vial, Jay A Bertrand

Acta Crystallogr D Biol Crystallogr· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design.
Giulia Canevari, Stefania Re Depaolini, Ulisse Cucchi, Jay A Bertrand, Elena Casale

Biochemistry· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alkylsulfanyl-1,2,4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure-activity relationships.
Paolo Polucci, Paola Magnaghi, Mauro Angiolini, Daniela Asa, Nilla Avanzi, Jay Bertrand

J Med Chem· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists.
Heidi L Perez, Patrizia Banfi, Jay Bertrand, Zhen-Wei Cai, James W Grebinski

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.
Michele Caruso, Barbara Valsasina, Dario Ballinari, Jay Bertrand, Maria Gabriella Brasca

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetramerization dynamics of C-terminal domain underlies isoform-specific cAMP gating in hyperpolarization-activated cyclic nucleotide-gated channels.
Marco Lolicato, Marco Nardini, Sabrina Gazzarrini, Stefan Möller, Daniela Bertinetti, Jay A Bertrand

J Biol Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural basis for CARM1 inhibition by indole and pyrazole inhibitors.
John S Sack, Sandrine Thieffine, Tiziano Bandiera, Marina Fasolini, Gerald J Duke, Jay A Bertrand

Biochem J· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.
Riccardo Colombo, Marina Caldarelli, Milena Mennecozzi, Maria Laura Giorgini, Francesco Sola, Jay Aaron Bertrand

Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Simona Bindi, Daniele Fancelli, Cristina Alli, Daniela Berta, Jay A Bertrand

Bioorg Med Chem· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Roberto T Bossi, M Beatrice Saccardo, Elena Ardini, Maria Menichincheri, Luisa Rusconi, Jay A Bertrand

Biochemistry· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Italo Beria, Dario Ballinari, Jay Aaron Bertrand, Daniela Borghi, Roberto Tiberio Bossi

J Med Chem· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
Maria Menichincheri, Alberto Bargiotti, Jens Berthelsen, Jay A Bertrand, Roberto Bossi

J Med Chem· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
David M Goldstein, Tom Alfredson, Jay Bertrand, Michelle F Browner, Ken Clifford

J Med Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
Anna Vulpetti, Patrizia Crivori, Alexander Cameron, Jay Bertrand, Maria Gabriella Brasca

J Chem Inf Model· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis